Loading...

APC/Cyanine7 anti-human CD19 Antibody

Pricing & Availability
Clone
HIB19 (See other available formats)
Regulatory Status
RUO
Workshop
V CD19.11
Other Names
B4
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
HIB19_APCCyanine7_CD19_Antibody_032019_updated.png
Human peripheral blood lymphocytes were stained with CD20 FITC and CD19 (clone HIB19) APC/Cyanine7 (left) or Mouse IgG1, ? isotype control (right)
  • HIB19_APCCyanine7_CD19_Antibody_032019_updated.png
    Human peripheral blood lymphocytes were stained with CD20 FITC and CD19 (clone HIB19) APC/Cyanine7 (left) or Mouse IgG1, ? isotype control (right)
Compare all formats See APC/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
302217 25 tests 123€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
302218 100 tests 249€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD19 is a 95 kD type I transmembrane glycoprotein also known as B4. It is a member of the immunoglobulin superfamily expressed on B-cells (from pro-B to blastoid B cells, absent on plasma cells) and follicular dendritic cells. CD19 is involved in B cell development, activation, and differentiation. CD19 forms a complex with CD21 (CR2) and CD81 (TAPA-1), and functions as a BCR co-receptor.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The CD19 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections8 and blocking of B cell proliferation. Clone HIB19 is not recommended for formalin-fixed paraffin-embedded sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 302267 & 302268).

 

Clone HIB19 partially blocks anti-human CD19 clones 4G7 and SJ25C1 staining based on in-house testing

Additional Product Notes

BioLegend is in the process of converting the name APC/Cy7 to APC/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our APC/Cyanine7 products. Please contact Technical Service if you have any questions.

Application References
  1. Schlossman S, et al. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  3. Bradbury L, et al. 1993. J. Immunol. 151:2915.
  4. Joseph A, et al. 2010. J. Virol. 84:6645. PubMed
  5. Wang X, et al. 2010. Haematologica. 95:884. (FC) PubMed
  6. Walker JD, et al. 2009. J. Immunol. 182:1548. (Block) PubMed
  7. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  8. Hansen A, et al. 2002. Arthritis Rheum. 46:2160. (IHC)
  9. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
  10. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
Product Citations
  1. Chabi S, et al. 2020. Cell Reports. 29(8):2307-2320.e6.. PubMed
  2. Sefik E, et al. 2022. Nature. 606:585. PubMed
  3. Zhao Y, et al. 2022. Front Immunol. 13:1041176. PubMed
  4. Pušnik J, et al. 2023. Nat Commun. 14:572. PubMed
  5. Chung Y, et al. 2014. J Vis Exp. 89: 51660. PubMed
  6. Yu B, et al. 2021. Cell. 184(7):1790-1803.e17. PubMed
  7. Woo MS, et al. 2021. iScience. 24(7):102752. PubMed
  8. Souter MNT, et al. 2022. J Exp Med. 219:. PubMed
  9. Bayik D, et al. 2022. Cancer Res. 82:4274. PubMed
  10. Shitaoka K, et al. 2023. Commun Biol. 6:395. PubMed
  11. Laine A, et al. 2023. Microorganisms. 11:. PubMed
  12. Taylor J, et al. 2023. Front Immunol. 14:1119350. PubMed
  13. Shoda H, et al. 2017. Arthritis Research & Therapy . 10.1186/s13075-017-1308-y. PubMed
  14. Pan YG, et al. 2022. Methods Mol Biol. 2574:31. PubMed
  15. Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
  16. Andonian BJ, et al. 2022. Sci Rep. 12:7450. PubMed
  17. Pozzetto B, et al. 2021. Nature. 600:701. PubMed
  18. Yamauchi T et al. 2018. Cancer cell. 33(3):386-400 . PubMed
  19. Novakova L et al. 2018. Journal of neurochemistry. 146(3):322-332 . PubMed
  20. Li Y, et al. 2021. Nat Commun. 12:87. PubMed
  21. Deng C, et al. 2016. Diabetes Care. 39: 434 - 440. PubMed
  22. Li H, et al. 2016. J Immunol. 196: 4064 - 4074. PubMed
  23. Nagafuchi Y, et al. 2016. Sci Rep. 6:29338. PubMed
  24. Tsuchida Y, et al. 2017. PLoS One. 10.1371/journal.pone.0169646. PubMed
  25. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  26. AC Belkina, JE Snyder-Cappione 2017. Cytometry A. 91:175-179. PubMed
  27. Wang H, et al. 2022. iScience. 25:105065. PubMed
  28. Zhou Y, et al. 2017. Front Cell Infect Microbiol. 7:457. PubMed
  29. Pan YG, et al. 2021. Immunity. 54(6):1245-1256.e5. PubMed
  30. Golovkin A, et al. 2021. Viruses. 13:. PubMed
  31. Frensch M, et al. 2021. Cell Mol Life Sci. 78:8165. PubMed
  32. Zhang X, et al. 2021. Front Immunol. 12:680068. PubMed
  33. Coelho CH, et al. 2020. JCI Insight. 5:. PubMed
  34. Kreutmair S, et al. 2021. Immunity. . PubMed
  35. Neff CP et al. 2018. EBioMedicine. 30:192-202 . PubMed
  36. Sinha D, et al. 2021. J Immunother Cancer. 9:. PubMed
  37. Kuebler P, et al. 2015. Proc Natl Acad Sci U S A. 112: 8379 - 8384. PubMed
  38. Kudryavtsev IV, et al. 2021. Curr Issues Mol Biol. 44:194. PubMed
  39. Punik J, et al. 2021. Cell Reports. 35(13):109320. PubMed
  40. Urlaub D, et al. 2019. Arthritis Res Ther. 1.067361111. PubMed
  41. Martín–Gayo E, et al. 2020. Cell Rep. 30:984. PubMed
  42. Arcangeli S, et al. 2022. J Clin Invest. 132: . PubMed
  43. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  44. Pahl MC, et al. 2022. Genome Biol. 23:125. PubMed
  45. Sefik E, et al. 2021. Nat Biotechnol. . PubMed
  46. James KR, et al. 2020. Nat Immunol. 1.113194444. PubMed
  47. Herati RS, et al. 2021. Cell Reports Medicine. 2(5):100262. PubMed
  48. Joseph A, et al. 2010. J Virol. 84:6645. PubMed
  49. Sitlinger A, et al. 2021. Cells. 10:. PubMed
  50. Samarani S, et al. 2020. Mediators Inflamm. 2020:6401969. PubMed
  51. Valestrand L, et al. 2022. Am J Pathol. . PubMed
  52. Liu W, et al. 2022. Bio Protoc. 12:e4285. PubMed
  53. Turaj AH et al. 2017. Cancer cell. 32(6):777-791 . PubMed
  54. Shemesh A, et al. 2022. J Exp Med. 219:. PubMed
  55. Sicklinger F, et al. 2021. J Clin Invest. 131:. PubMed
  56. Simpfendorfer K, et al. 2012. Hum Mol Genet. 21:3918. PubMed
  57. Shehata L, et al. 2019. Cell Rep. 28:3300. PubMed
  58. Zhang J, et al. 2015. J Biol Chem. 290 19093 . PubMed
  59. Körner C et al. 2017. Cell host & microbe. 22(1):111-119 . PubMed
  60. Lee J, et al. 2015. J Exp Med. 212:385. PubMed
  61. Breton G, et al. 2015. J Exp Med. 212:401. PubMed
  62. Suzuki D, et al. 2020. Stem Cell Reports. 14:49. PubMed
  63. Sander J et al. 2017. Immunity. 47(6):1051-1066 . PubMed
  64. Shehata L, et al. 2019. Nat Commun. 10:1126. PubMed
  65. Bianchi A, et al. 2022. Genome Biol. 23:229. PubMed
  66. Corrado M, et al. 2020. Cell Metab. 32:981. PubMed
  67. Tomellini E, et al. 2020. Cell Reports. 28(4):1063-1073.e5.. PubMed
  68. Hui Z, et al. 2022. Cell Death Dis. 13:607. PubMed
  69. Sananez I, et al. 2021. EBioMedicine. 72:103615. PubMed
RRID
AB_314247 (BioLegend Cat. No. 302217)
AB_314248 (BioLegend Cat. No. 302218)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, 95 kD
Distribution

B lineage (except plasma cells), follicular dendritic cells

Function
B cell activation and differentiation
Ligand/Receptor
Forms complex with CD21 (CR2) and CD81 (TAPA-1), BCR coreceptor
Cell Type
B cells, Dendritic cells
Biology Area
Costimulatory Molecules, Immunology
Molecular Family
CD Molecules
Antigen References

1. Tedder T, et al. 1994. Immunol. Today 15:437.
2. Bradbury L, et al. 1993. J. Immunol. 151:2915.

Gene ID
930 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD19
Specificity Alt (DOES NOT SHOW ON TDS):
CD19
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD19 on UniProt.org

Other Formats

View All CD19 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-human CD19 HIB19 FC
Biotin anti-human CD19 HIB19 FC
FITC anti-human CD19 HIB19 FC
PE anti-human CD19 HIB19 FC
PE/Cyanine5 anti-human CD19 HIB19 FC
Purified anti-human CD19 HIB19 FC,CyTOF®,IHC-F
APC/Cyanine7 anti-human CD19 HIB19 FC
PE/Cyanine7 anti-human CD19 HIB19 FC
Alexa Fluor® 488 anti-human CD19 HIB19 FC,ICC
Alexa Fluor® 647 anti-human CD19 HIB19 FC,IHC-F
Pacific Blue™ anti-human CD19 HIB19 FC
Alexa Fluor® 700 anti-human CD19 HIB19 FC
PerCP anti-human CD19 HIB19 FC
PerCP/Cyanine5.5 anti-human CD19 HIB19 FC
Brilliant Violet 421™ anti-human CD19 HIB19 FC,ICC,IHC-F
Brilliant Violet 570™ anti-human CD19 HIB19 FC
Brilliant Violet 650™ anti-human CD19 HIB19 FC
Brilliant Violet 785™ anti-human CD19 HIB19 FC
Brilliant Violet 510™ anti-human CD19 HIB19 FC
Brilliant Violet 605™ anti-human CD19 HIB19 FC
Brilliant Violet 711™ anti-human CD19 HIB19 FC
Purified anti-human CD19 (Maxpar® Ready) HIB19 FC,CyTOF®
Alexa Fluor® 594 anti-human CD19 HIB19 ICC,IHC-F
PE/Dazzle™ 594 anti-human CD19 HIB19 FC
PE anti-human CD19 HIB19 FC
APC/Fire™ 750 anti-human CD19 HIB19 FC
Pacific Blue™ anti-human CD19 HIB19 FC
APC anti-human CD19 HIB19 FC
PE/Cyanine7 anti-human CD19 HIB19 FC
TotalSeq™-A0050 anti-human CD19 HIB19 PG
Brilliant Violet 750™ anti-human CD19 HIB19 FC
TotalSeq™-B0050 anti-human CD19 HIB19 PG
TotalSeq™-C0050 anti-human CD19 HIB19 PG
PerCP/Cyanine5.5 anti-human CD19 HIB19 FC
Spark NIR™ 685 anti-human CD19 HIB19 FC
Ultra-LEAF™ Purified anti-human CD19 HIB19 FC,CyTOF®,Block,IHC
APC/Fire™ 810 anti-human CD19 HIB19 FC
PE/Fire™ 640 anti-human CD19 HIB19 FC
PE/Fire™ 700 anti-human CD19 HIB19 FC
TotalSeq™-D0050 anti-human CD19 HIB19 PG
Spark YG™ 593 anti-human CD19 HIB19 FC
GMP Pacific Blue™ anti-human CD19 HIB19 FC
Spark Violet™ 423 anti-human CD19 HIB19 FC
GMP PE anti-human CD19 HIB19 FC
GMP APC anti-human CD19 HIB19 FC
KIRAVIA Blue 520™ anti-human CD19 HIB19 FC
GMP PerCP/Cyanine5.5 anti-human CD19 HIB19 FC
GMP PE/Cyanine7 anti-human CD19 HIB19 FC
Spark Violet™ 500 anti-human CD19 HIB19 FC
PE/Fire™ 810 anti-human CD19 HIB19 FC
Spark Violet™ 423 anti-human CD19 HIB19 FC
Spark UV™ 387 anti-human CD19 HIB19 FC
APC/Fire™ 750 anti-human CD19 HIB19 FC
PE/Cyanine5 anti-human CD19 HIB19 FC
Alexa Fluor® 660 anti-human CD19 HIB19 FC
PerCP/Fire™ 806 anti-human CD19 HIB19 FC
PerCP/Fire™ 780 anti-human CD19 HIB19 FC
Spark PLUS UV™ 395 anti-human CD19 HIB19 FC
Spark Red™ 718 anti-human CD19 HIB19 FC
Go To Top Version: 4    Revision Date: 03.20.2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account